{"status":"success","data":{"title":"Vasopressors and Inotropes in Shock","slug":"vasopressors-inotropes-shock","tags":["epinephrine","Phenylephrine","norepinephrine","dopamine","dobutamine"],"collection":["cardiovascular","critical care"],"content":"\n# Vasopressors and Inotropes in Shock\n\nThe treatment of shock should focus on correcting the underlying pathophysiology. With persistent hemodynamic instability, a vasopressor and/or inotrope should be selected. Reviewing receptor physiology can help you select the best-fit agent for the patient's clinical condition.\n\n## Physiologic Categories of Shock\n\n-   **Cardiogenic:**\n    -   *Intrinsic disease*: myopathy, AMI, valvular dysfunction, arrhythmia\n    -   *Extrinsic disease*: obstructive disorders (PE, pericardial tamponade, tension PTX)\n-   **Hypovolemic:** bleeding, diarrhea, burns, third-spacing\n-   **Distributive:** sepsis, anaphylaxis, toxic shock syndrome, central neurologic injury\n\n## Receptor Physiology\n\n**Alpha-adrenergic receptors**\n\n-   Alpha-1 agonists cause vasoconstriction\n-   Alpha-2 agonists causes vasodilatation esp. of coronary arteries\n\n**Beta-adrenergic receptors**\n\n-   Beta-1 agonists increases HR and cardiac contractility → increased CO\n-   Beta-2 agonists dilate small coronary A’s, visceral organ A’s, skeletal muscle A’s and increase bronchodilation\n\n**Dopaminergic receptors**\n\n-   7 types of dopamine receptors.\n-   D4 agonists increase cardiac contractility\n-   D1 and D2 agonists increase renal diuresis and naturesis\n\n**Vasopressin receptors**\n\n-   V1 agonists cause vasoconstriction mostly in peripheral arterioles\n\n## Medications\n\n**<class span=\"drug\">Epinephrine</span>**\n\n-   Full range of alpha and beta agonist properties\n-   Risk of dysrhythmias, AMI, abdominal organ ischemia\n-   Dose 2-10 mcg/min mostly increases beta-1 effects\n-   Dose &gt;10 mcg/min mostly increases alpha effects\n\n**<class span=\"drug\">Phenylephrine</span>**\n\n-   Pure alpha agonist activity and minimally affects cardiac function directly\n\n**<class span=\"drug\">Norepinephrine</span>**\n\n-   Alpha and beta agonist activity\n-   Dose &lt; 2 mcg/min mostly beta-agonist effects\n-   Dose &gt; 3 mcg/min adds alpha agonist effects\n-   First line agent to improve BP for septic shock\n\n**<class span=\"drug\">Dopamine</span>**\n\n-   Dose 0.5-2 mcg/kg/min stimulates D1 receptors\n-   Dose 2-5 mcg/kg/min stimulates norepinephrine release\n-   Dose 5-10 mcg/kg/min stimulates beta-1 activity\n-   Dose &gt;10 mcg/kg/min stimulates both beta-1 and alpha activity\n-   *Surviving Sepsis Campaign* recommends **dopamine** or **norepi** as 1st-line agents\n\n**<class span=\"drug\">Dobutamine</span>**\n\n-   Mainly beta-1 agonist --&gt; increased SV and CO with minimal affect on SVR\n-   Less myocardial oxygen consumption\n\n## Vasopressors and inotropes in shock (table)\n\n![](https://d2p53dh3qxfm0x.cloudfront.net/uploads/img/1jx/5/m/b05f6e95-0a29-531e-af1f-c4ab1bd445fc/640.png)\nFrom [Ellender TJ, Skinner JC. Emerg Med Clin North Am. 2008](http://www.ncbi.nlm.nih.gov/pubmed/18655944)\n\n## References\n\n-   [Ellender TJ, Skinner JC. Emerg Med Clin North Am. 2008 Aug;26(3):759-86.](http://www.ncbi.nlm.nih.gov/pubmed/18655944)\n"}}